MedPacto, Inc. (KOSDAQ:235980)
South Korea
· Delayed Price · Currency is KRW
3,110.00
+50.00 (1.63%)
Apr 1, 2025, 3:30 PM KST
MedPacto Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Selling, General & Admin | 3,613 | 4,427 | 5,021 | 4,607 | 3,535 |
Research & Development | 18,018 | 24,164 | 31,919 | 24,551 | 23,962 |
Other Operating Expenses | - | - | - | 12.46 | 13.91 |
Operating Expenses | 21,807 | 28,752 | 37,246 | 29,459 | 27,800 |
Operating Income | -21,807 | -28,752 | -37,246 | -29,459 | -27,800 |
Interest Expense | -91.94 | -493.23 | -9,621 | -7,769 | -31.27 |
Interest & Investment Income | 1,687 | 388.46 | 1,324 | 663.52 | 508.79 |
Earnings From Equity Investments | -424.3 | -390.44 | - | - | -248.59 |
Currency Exchange Gain (Loss) | -116.09 | 114.09 | 25.05 | -19.66 | -146.41 |
Other Non Operating Income (Expenses) | 85.4 | 64.07 | 9,272 | 19,278 | 151.9 |
EBT Excluding Unusual Items | -20,667 | -29,069 | -36,246 | -17,306 | -27,566 |
Gain (Loss) on Sale of Investments | 526.5 | 350.51 | 492.28 | 266.33 | 2,213 |
Gain (Loss) on Sale of Assets | - | -5.93 | - | - | - |
Other Unusual Items | - | -6,600 | - | - | - |
Pretax Income | -20,140 | -35,325 | -35,753 | -17,040 | -25,352 |
Net Income | -20,140 | -35,325 | -35,753 | -17,040 | -25,352 |
Net Income to Common | -20,140 | -35,325 | -35,753 | -17,040 | -25,352 |
Shares Outstanding (Basic) | 34 | 21 | 33 | 20 | 20 |
Shares Outstanding (Diluted) | 34 | 21 | 33 | 20 | 20 |
Shares Change (YoY) | 58.75% | -36.21% | 62.45% | 0.88% | - |
EPS (Basic) | -598.00 | -1665.00 | -1075.00 | -832.30 | -1249.24 |
EPS (Diluted) | -598.00 | -1665.00 | -1075.00 | -832.30 | -1249.24 |
Free Cash Flow | -16,873 | -26,402 | -30,491 | -25,909 | -24,100 |
Free Cash Flow Per Share | -500.99 | -1244.42 | -916.79 | -1265.52 | -1187.53 |
EBITDA | -20,265 | -26,919 | -35,380 | -27,736 | -26,363 |
D&A For EBITDA | 1,542 | 1,833 | 1,866 | 1,723 | 1,437 |
EBIT | -21,807 | -28,752 | -37,246 | -29,459 | -27,800 |
Source: S&P Global Market Intelligence. Standard template.
Financial Sources.